Work

Table 3 from Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors

Year: 2026

Type: other

Abstract: Best overall response by RECIST 1.1 for VV1 monotherapy and in combination with avelumab (parts 1–3).

DOI: 10.1158/2767-9764.33205520

Authors: Jaime R. Merchan, Manish R. Patel, Timothy P. Cripe, Matthew O. Old, Jen Boughton, Rosa M. Diaz, Kah-Whye Peng, Stephen J. Russell, Luke Russell, Nandakumar Packiriswamy, Erol Wiegert, Alice S. Bexon, Steven F. Powell

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W7202159385

Cites:

Cited by:

Related to: